Omeprazole
Proton pump inhibitor. Increases the in vitro anti-SARS-CoV-2 activity of remdesivir, through two possible mechanisms: lysosomotropic; off-target cysteine protease inhibition. Bojkova et al. bioRxiv, Apr 5 2020, https://doi.org/10.1101/2020.04.03.024257.
- Datasheet: view or download
- Applications:Approved drug (U.S.); in COVID-19 clinical trials
Biochemicals & reagents
73590-58-6
1) H Satoh et al. J. Pharmacol. Exp. Ther. 1989 248:806 2. M Kuzin et al. Clin. Pharmacokinet. 2018 57:729 3. A Schmarda et al. Br. J. Pharmacol. 2000 129:598 4. Y Maejima et al. Peptides 2020 128:170312 5. SM Watanabe et al. Sci. Rep. 2020 10:4003
345.4
-20°C (des.)
Omeprazole is a H+, K+-ATPase inhibitor with a IC50 = 5.8 μM. This compound is clinically relevant as an antisecretory and antiulcer agent (1), is a potent inhibitor of CYP2C19 (Ki=3.1 uM) (2) and inhibits swelling-dependent chloride channels (3). It also facilitates oral bioavailability of bioactive peptides such as oxytocin by raising stomach pH4 and displays broad spectrum antiviral activity (5).